| Disease Domain | Count |
|---|---|
| Infectious Diseases | 8 |
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 8 |
Target- |
Mechanism Mycobacterium tuberculosis inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Mycobacterium tuberculosis inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Mycobacterium tuberculosis inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date15 Dec 2025 |
Sponsor / Collaborator |
Start Date01 Aug 2025 |
Sponsor / Collaborator |
Start Date01 Jun 2025 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
GSX-358607A | Tuberculosis More | Preclinical |
Compound 18c(PUCRS) | Tuberculosis More | Preclinical |
INCT-TB422 | Tuberculosis More | Preclinical |
5-Fluoroindole | Tuberculosis More | Preclinical |
INCT-TB765 | Tuberculosis More | Preclinical |





